The "Diabetic Retinopathy - Pipeline Insight, 2026" report reveals that more than 50 companies are developing over 55 drugs targeting diabetic retinopathy, a leading cause of vision loss in diabetics. Key drugs in late-stage development include Tarcocimab, an anti-VEGF therapy by Kodiak Sciences, and THN391, which targets fibrin-mediated inflammation. The report highlights diverse therapeutic approaches, clinical trial phases, and administration routes, signaling robust innovation aimed at improving treatment outcomes. This comprehensive pipeline analysis underscores significant growth opportunities and evolving strategies in diabetic retinopathy care through 2026.
Christian Dior SE disclosed its monthly update on the total number of shares and voting rights composing its share capital as of June 30, 2026. The company reported 180,507,516 total shares and a gross total of 356,945,619 voting rights, with a net t...
The osteosarcoma treatment pipeline features over 25 companies developing more than 32 drugs, highlighting strong R&D activity in this bone cancer field. Key drugs in late-stage trials include HS-20093, an antibody-drug conjugate targeting B7-H3, and...
The Shenzhen Chamber of Commerce, led by President Lin Hui, visited Munich to attend The smarter E Europe exhibition, focusing on new energy collaboration between China and Europe. The delegation engaged with European companies on photovoltaics, ener...
UBS Group AG has notified Bang & Olufsen A/S that its shareholding and voting rights have fallen below 5% as of July 1, 2026. UBS now holds 6,784,164 shares, representing 4.60% of the total share capital and voting rights in Bang & Olufsen. This upda...
Flexible Solutions International has traded its remaining 19.9% equity in FL LLC to secure exclusive rights to manufacture and sell four agricultural products across Central and South America, the Caribbean, and south of the Mexico-US border. This fo...
